These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27742637)

  • 1. A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground.
    Srivastava S; Deshpande D; Pasipanodya JG; Thomas T; Swaminathan S; Nuermberger E; Gumbo T
    Clin Infect Dis; 2016 Nov; 63(suppl 3):S75-S79. PubMed ID: 27742637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks.
    Srivastava S; Deshpande D; Pasipanodya J; Nuermberger E; Swaminathan S; Gumbo T
    Clin Infect Dis; 2016 Nov; 63(suppl 3):S102-S109. PubMed ID: 27742641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.
    Deshpande D; Srivastava S; Nuermberger E; Pasipanodya JG; Swaminathan S; Gumbo T
    Clin Infect Dis; 2016 Nov; 63(suppl 3):S88-S94. PubMed ID: 27742639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis.
    Jeena PM; Bishai WR; Pasipanodya JG; Gumbo T
    Antimicrob Agents Chemother; 2011 Feb; 55(2):539-45. PubMed ID: 21098246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way.
    Deshpande D; Srivastava S; Nuermberger E; Pasipanodya JG; Swaminathan S; Gumbo T
    Clin Infect Dis; 2016 Nov; 63(suppl 3):S95-S101. PubMed ID: 27742640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies.
    Srivastava S; Pasipanodya JG; Ramachandran G; Deshpande D; Shuford S; Crosswell HE; Cirrincione KN; Sherman CM; Swaminathan S; Gumbo T
    EBioMedicine; 2016 Apr; 6():126-138. PubMed ID: 27211555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges in childhood tuberculosis.
    Swaminathan S; Ramachandran G
    Clin Pharmacol Ther; 2015 Sep; 98(3):240-4. PubMed ID: 26088359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps.
    Deshpande D; Srivastava S; Pasipanodya JG; Bush SJ; Nuermberger E; Swaminathan S; Gumbo T
    Clin Infect Dis; 2016 Nov; 63(suppl 3):S80-S87. PubMed ID: 27742638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis.
    Drusano GL; Neely M; Van Guilder M; Schumitzky A; Brown D; Fikes S; Peloquin C; Louie A
    PLoS One; 2014; 9(7):e101311. PubMed ID: 25003557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ethambutol in paediatric tuberculosis: aspects of ethambutol serum concentration, efficacy and toxicity in children.
    Thee S; Detjen A; Quarcoo D; Wahn U; Magdorf K
    Int J Tuberc Lung Dis; 2007 Sep; 11(9):965-71. PubMed ID: 17705973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
    Gumbo T; Louie A; Deziel MR; Parsons LM; Salfinger M; Drusano GL
    J Infect Dis; 2004 Nov; 190(9):1642-51. PubMed ID: 15478070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of the use of ethionamide and prothionamide in childhood tuberculosis.
    Thee S; Garcia-Prats AJ; Donald PR; Hesseling AC; Schaaf HS
    Tuberculosis (Edinb); 2016 Mar; 97():126-36. PubMed ID: 26586647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo modeling of tuberculosis drugs and its impact on optimization of doses and regimens.
    Srivastava S; Gumbo T
    Curr Pharm Des; 2011; 17(27):2881-8. PubMed ID: 21834761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partnerships to Design Novel Regimens to Treat Childhood Tuberculosis, Sui Generis: The Road Ahead.
    Gumbo T; Makhene MK; Seddon JA
    Clin Infect Dis; 2016 Nov; 63(suppl 3):S110-S115. PubMed ID: 27742642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antituberculosis drugs in children.
    Schaaf HS; Garcia-Prats AJ; Donald PR
    Clin Pharmacol Ther; 2015 Sep; 98(3):252-65. PubMed ID: 26095192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests.
    Swaminathan S; Pasipanodya JG; Ramachandran G; Hemanth Kumar AK; Srivastava S; Deshpande D; Nuermberger E; Gumbo T
    Clin Infect Dis; 2016 Nov; 63(suppl 3):S63-S74. PubMed ID: 27742636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing.
    van Rijn SP; Srivastava S; Wessels MA; van Soolingen D; Alffenaar JC; Gumbo T
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations.
    Gumbo T; Louie A; Liu W; Brown D; Ambrose PG; Bhavnani SM; Drusano GL
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2329-36. PubMed ID: 17438043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.
    Pasipanodya JG; Nuermberger E; Romero K; Hanna D; Gumbo T
    Clin Infect Dis; 2015 Aug; 61 Suppl 1():S10-7. PubMed ID: 26224767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program.
    Ellis JM; Kuti JL; Nicolau DP
    Clin Ther; 2005 Nov; 27(11):1820-30. PubMed ID: 16368453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.